C3 raises $10m

CLINICAL Cell Culture has raised $10 million after completing a share placement of 28.6 million fully paid ordinary shares to Australian investors.At an issue price of 35 cents a share, the placement represented a discount of 33 per cent to the three-month volume-weighted average price for C3 shares for the three-month preceding period. C3 managing director Troels Jordansen said the company already had sufficient cash to achieve its objectives, but with a better than expected response to the company’s product, the board decided to further strengthen the balance sheet to fund profitable growth.Following the placement, C3’s cash reserves sit at $18.2 million, with plans for the new funds to be used in launching the company’s ReCell skin grafting product in Europe, Japan and the Americas this year, with Food and Drug Administration approval expected in the US by September or October.

Add your comment

BNIQ sponsored byECU School of Business and Law


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE9,064
10th-The University of Notre Dame Australia6,708
46 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer